Atlas Trials

Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Clinical trial NCT01363817 · COMPLETED

Trial details

NCT number
NCT01363817
Sponsor
Bristol-Myers Squibb
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Lymphoblastic Leukemia, Acute T-cellPrecursor T-Cell Lymphoblastic Lymphoma
Start date
2011-09-28
Primary completion
2018-02-07
Enrollment
31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.